Personal information

No personal information available

Activities

Employment (2)

University of Washington School of Medicine: Seattle, WA, US

Assistant Professor (Pediatrics)
Employment
Source: Self-asserted source
Sonya Heltshe

Seattle Children's Research Institute: Seattle, WA, US

Director of Biostatistics (CFF Therapeutics Development Network)
Employment
Source: Self-asserted source
Sonya Heltshe

Education and qualifications (2)

University of Virginia: Charlottesville, VA, US

B.A.
Education
Source: Self-asserted source
Sonya Heltshe

Colorado School of Public Health: Denver, CO, US

PhD (Biostatistics)
Education
Source: Self-asserted source
Sonya Heltshe

Professional activities (2)

International Biometric Society: Washington, DC, US

Membership
Source: Self-asserted source
Sonya Heltshe

American Statistical Association: Alexandria, VA, US

Membership
Source: Self-asserted source
Sonya Heltshe

Funding (1)

CFFT

Grant
Cystic Fibrosis Foundation (Bethesda, MD, US)
Source: Self-asserted source
Sonya Heltshe

Works (9)

Statistical approaches for the integration of external controls in a cystic fibrosis clinical trial: a simulation and an application

American Journal of Epidemiology
2024-12-02 | Journal article
Contributors: Mark N Warden; Sonya L Heltshe; Noah Simon; Stephen J Mooney; Nicole Mayer-Hamblett; Amalia S Magaret
Source: check_circle
Crossref

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients

Journal of Cystic Fibrosis
2021-03 | Journal article
Contributors: Amir Moheet; Daniel Beisang; Lin Zhang; Scott D. Sagel; Jill M. VanDalfsen; Sonya L. Heltshe; Carla Frederick; Michelle Mann; Nicholas Antos; Joanne Billings et al.
Source: check_circle
Crossref

Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis

Journal of Cystic Fibrosis
2021-03 | Journal article
Contributors: Donald R. VanDevanter; Sonya L. Heltshe; Jay B. Hilliard; Michael W. Konstan
Source: check_circle
Crossref

Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment

Journal of Cystic Fibrosis
2021-01 | Journal article
Contributors: DR VanDevanter; SL Heltshe; DB Sanders; NE West; M Skalland; PA Flume; CH Goss
Source: check_circle
Crossref

Real-world evidence in cystic fibrosis modulator development: Establishing a path forward

Journal of Cystic Fibrosis
2020-05 | Journal article
Contributors: Amalia Magaret; Mark Warden; Noah Simon; Sonya Heltshe; Nicole Mayer-Hamblett
Source: check_circle
Crossref

Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation

Annals of the American Thoracic Society
2020-02 | Journal article
Contributors: J. Kirk Harris; Brandie D. Wagner; Edith T. Zemanick; Charles E. Robertson; Mark J. Stevens; Sonya L. Heltshe; Steven M. Rowe; Scott D. Sagel
Source: check_circle
Crossref

CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis

Annals of the American Thoracic Society
2019-03 | Journal article
Contributors: Alex H. Gifford; Sonya L. Heltshe; Christopher H. Goss
Source: check_circle
Crossref

Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF

Contemporary Clinical Trials
2018-01 | Journal article
Contributors: Sonya L. Heltshe; Natalie E. West; Donald R. VanDevanter; D.B. Sanders; Valeria V. Beckett; Patrick A. Flume; Christopher H. Goss
Source: check_circle
Crossref

Forced expiratory volume in 1 second variability in cystic fibrosis—has the clinical utility been lost in statistical translation?

The Journal of Pediatrics
2016-05 | Journal article
Contributors: Sonya L. Heltshe; Rhonda D. Szczesniak
Source: check_circle
Crossref